Killer cell immunoglobulin-like receptor 3DS1 (KIR3DS1)

Killer cell immunoglobulin-like receptor 3DS1 (KIR3DS1) is an activating receptor expressed by natural killer (NK) cells and some T lymphocytes[1][2][3][5]. Structurally, it is a type I transmembrane glycoprotein characterized by three extracellular immunoglobulin domains (D0, D1, D2) and a short cytoplasmic tail, which lacks inhibitory motifs but contains features that recruit the DAP12 adaptor to promote activating ITAM-dependent signaling[1][2][3][5]. KIR3DS1 is encoded on chromosome 19q13.4 within the leukocyte receptor complex and is almost monomorphic. Unlike its inhibitory counterpart KIR3DL1, which is highly polymorphic, KIR3DS1 triggers NK cell activation and cytokine secretion and is implicated in antiviral immunity—particularly in conjunction with certain HLA class I alleles (notably HLA-Bw4-I80, though direct ligand interaction remains unconfirmed)[2][3][4]. Genetically, presence of KIR3DS1 has been associated with outcomes in viral infections (especially better control of HIV-1), malignancies, autoimmune diseases, and graft-versus-host disease[2][3][4][6]. KIR3DS1 status is sometimes evaluated as a biomarker in disease association studies, though no specific drugs directly target or modulate this receptor in clinical practice. Safety concerns stem from its potential role in promoting unintended NK cell activation leading to tissue damage or abnormal lymphoproliferation[6].

Other names

KIR3DS1NKAT10NKAT-10nkat10Natural killer-associated transcript 10Killer cell immunoglobulin-like receptor, three Ig domains and short cytoplasmic tail 1

Modulation of NK cell activation via engagement of DAP12 adaptor (ITAM signaling); Alteration of immune surveillance of virally infected or malignant cells